Advancing cancer immunotherapy: a vision for the field.
作者信息
de Miranda Noel F C C, Trajanoski Zlatko
机构信息
Department of Pathology, Leiden University Medical Centre, Albinusdreef, 2333 ZA, Leiden, The Netherlands.
Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innrain, 6020, Innsbruck, Austria.
出版信息
Genome Med. 2019 Jul 29;11(1):51. doi: 10.1186/s13073-019-0662-6.
Abstract
摘要
相似文献
1
Advancing cancer immunotherapy: a vision for the field.
Genome Med. 2019 Jul 29;11(1):51. doi: 10.1186/s13073-019-0662-6.
2
Combining radiotherapy with immunotherapy: the past, the present and the future.
Br J Radiol. 2017 Aug;90(1076):20170157. doi: 10.1259/bjr.20170157. Epub 2017 May 25.
3
A new era for cancer immunotherapy based on the genes that encode cancer antigens.
Immunity. 1999 Mar;10(3):281-7. doi: 10.1016/s1074-7613(00)80028-x.
4
Conference scene: Immune signatures in the tumor and beyond.
Immunotherapy. 2012 Aug;4(8):761-72. doi: 10.2217/imt.12.70.
5
The case for cancer immunotherapy.
Drug Discov Today. 2003 Jun 15;8(12):530-1. doi: 10.1016/s1359-6446(03)02727-2.
6
Overview: immunotherapy for cancer--is it time for the kitchen sink?
Curr Opin Investig Drugs. 2002 Jan;3(1):130-1.
7
First conference on cancer immunotherapy gets "explosion of interest".
BMJ. 2015 Sep 11;351:h4876. doi: 10.1136/bmj.h4876.
8
The role of immunotherapy in oncology.
Future Oncol. 2015;11(21):2861-4. doi: 10.2217/fon.15.237. Epub 2015 Sep 25.
9
Delivering safer immunotherapies for cancer.
Adv Drug Deliv Rev. 2017 May 15;114:79-101. doi: 10.1016/j.addr.2017.05.011. Epub 2017 May 22.
10
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4.
引用本文的文献
1
Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy.
Pharmaceutics. 2025 Jul 22;17(8):948. doi: 10.3390/pharmaceutics17080948.
2
The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma.
Cancers (Basel). 2021 Nov 18;13(22):5789. doi: 10.3390/cancers13225789.
3
Editorial: Big Data and Machine Learning in Cancer Genomics.
Front Genet. 2021 Sep 20;12:749584. doi: 10.3389/fgene.2021.749584. eCollection 2021.
4
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.
J Exp Clin Cancer Res. 2021 Oct 1;40(1):311. doi: 10.1186/s13046-021-02111-5.
5
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.
J Exp Clin Cancer Res. 2021 Jul 23;40(1):240. doi: 10.1186/s13046-021-02023-4.
6
Resistance is not the end: lessons from pest management.
Cancer Control. 2020 Jan-Dec;27(1):1073274820922543. doi: 10.1177/1073274820922543.
7
Hypoxia increases mutational load of breast cancer cells through frameshift mutations.
Oncoimmunology. 2020 Apr 16;9(1):1750750. doi: 10.1080/2162402X.2020.1750750. eCollection 2020.
8
A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry.
Front Immunol. 2019 Oct 29;10:2534. doi: 10.3389/fimmu.2019.02534. eCollection 2019.
本文引用的文献
1
High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity.
Gut. 2020 Apr;69(4):691-703. doi: 10.1136/gutjnl-2019-318672. Epub 2019 Jul 3.
2
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system.
Genome Med. 2019 Jun 20;11(1):40. doi: 10.1186/s13073-019-0653-7.
3
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.
Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6.
4
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
5
Discovery and characterization of actionable tumor antigens.
Genome Med. 2019 Apr 30;11(1):29. doi: 10.1186/s13073-019-0642-x.
6
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Genome Med. 2019 Apr 30;11(1):28. doi: 10.1186/s13073-019-0636-8.
7
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Nat Rev Cancer. 2019 Mar;19(3):133-150. doi: 10.1038/s41568-019-0116-x.
8
Cancer Neoantigens.
Annu Rev Immunol. 2019 Apr 26;37:173-200. doi: 10.1146/annurev-immunol-042617-053402. Epub 2018 Dec 14.
9
Noncoding regions are the main source of targetable tumor-specific antigens.
Sci Transl Med. 2018 Dec 5;10(470). doi: 10.1126/scitranslmed.aau5516.
10
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.
Nat Med. 2019 Jan;25(1):89-94. doi: 10.1038/s41591-018-0266-5. Epub 2018 Dec 3.
Zotero 插件